First patients suffering from severe emphysema treated with
27 January 2012
The first commercial use of Uptake Medical's InterVapor, a
system for endoscopic lung volume reduction in patients with severe
emphysema, was made in Germany last November.
The patient successfully underwent treatment with InterVapor, an
endoscopic lung volume reduction system for the treatment of severe
emphysema that uses the body’s natural healing processes without
leaving foreign materials in the lung. The patient was treated by
the team at the Thoraxklinik in Heidelberg, Germany, which is led by
Professor Dr Felix Herth and is recognized as a leading institution
for pioneering new therapeutic options for people with emphysema.
“As investigators in the VAPOR trial, we observed the benefits
our patients received from InterVapor and we are pleased to be
selected to introduce InterVapor,” commented Professor Dr. Felix
Herth, chief, Department of Pulmonary Medicine, Thoraxklinik
Heidelberg. “It is particularly fitting that the first patient case
has taken place in November, which marks COPD Awareness month, as
InterVapor offers a new treatment option for patients who are
looking for relief from their emphysema.”
Uptake Medical announced on 9 Jan this year that it had closed on
a Series C funding round. The round was led by Singapore-based
Crescent Point Group, with existing investors, Maverick Capital,
ONSET Ventures, GBS Venture Partners, WRF Capital, Arboretum
Ventures and Affinity Capital, making additional investments. Sami
Sindi, Crescent Point managing partner, will join the Uptake Medical
board of directors. Moelis & Company acted as financial advisor to
the company in connection with the funding.
The company received CE mark approval for InterVapor in September
and recently announced TGA approval for InterVapor to be marketed in
R. King Nelson, president and chief executive officer of Uptake
Medical, commented, “Finalizing this very successful round of
financing represents another positive step for Uptake Medical. We
are thrilled with the addition of Crescent Point to our board and we
are equally pleased that our current investors remain committed to
Uptake Medical as we continue the commercialization of InterVapor.”
Emphysema is a progressive disease in which the lungs are
permanently damaged. This leads to a condition called
hyperinflation, which impacts breathing function and forces patients
to take short, shallow breaths, severely impacting quality of life.
The InterVapor System directly induces reduction of hyperinflation,
a problem for patients with severe emphysema. It is a non-surgical
procedure which treats hyperinflated parts of the lungs with heated
water vapor, and triggers the body’s natural healing process,
gradually reducing the treated portion of the lungs and increasing
the ability to breathe more fully.
Unlike other approaches to lung volume reduction, InterVapor does
not leave foreign materials in the lung, which may require
additional procedures for adjustment or removal. Results from the
VAPOR trial demonstrated clinically significant improvements in lung
function and quality of life for patients with severe emphysema.
The global incidence of Chronic Obstructive Pulmonary Disease
(COPD), which includes emphysema, is on the rise and will become the
third leading cause of death by 2030. In the US, where nearly 5
million people are diagnosed with emphysema, it already holds this
position with one person dying every 4 minutes from COPD.
Debilitating and costly, nearly $50 billion was spent addressing the
direct and indirect costs associated with COPD in the U.S. in 2010.
Source: Uptake Medical